This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
Rentech (RTK - Snapshot Report) is
seeing estimates for 2013 slide deeper and as a result it
is a Zacks Rank #5 (Strong Sell).
It is the Bear of the Day.
Moving to the NASDAQ Capital Market
Yesterday, the company announced that it will transfer its listing from the NYSE to the NASDAQ Capital Market effective with the start of trading on August 13, 2013. Rentech will continue to trade under its existing ticker symbol "RTK." Rentech's common stock will trade on the NYSE MKT until the close of trading on August 12, 2013.
Rentech engages in the sale of natural-gas based nitrogen fertilizer products in the United States and Brazil. Its products include ammonium sulfate, sulfuric acid, and ammonium thiosulfate used in the production of corn, soybeans, potatoes, cotton, canola, alfalfa, and wheat. Rentech, Inc. was founded in 1980 and is based in Los Angeles, California.
Over the last six earnings reports, the RTK hasn't done so well. I see one beat in for the September 2012 quarter. There were two earnings meets and three earnings misses.
Two of the three earnings misses have been the last two reported quarters. The negative earnings surprises both came with Wall Street looking for the company to report either a gain or a breakeven quarter, and both times the company reported a loss in the quarter.
Earnings Estimates Not Growing
Estimates for RTK have declined of late. The 2013 estimates
are moving lower, but not by that much. Peaking at $0.14 in
March they have ticked lower to $0.07 in April. They have since slide to $0.02.
The 2014 Zacks Consensus Estimate seen a more dramatic collapse, with estimates moving from $0.26 in June to $0.14 at the current level.
The valuation picture for RTK is off the charts. By off the charts I mean that the industry averages are negative, not allowing for a proper comparison. Still the 107X trailing PE is huge, but bigger still is the 142.7x forward PE. The Price to book multiple of 2.6x is a good sized premium to the industry average of 1.9x. The price to sales metric has the company trading at 1.7x vs the 1.1x for the industry.
The price and consensus chart really tells the story here as the estimate lines for 2013 and 2014 have recently taken a nosedive. That dive lower in estimates comes a little after the stock fell from $3 to $2.25. The problem is, estimates may still fall further, which will lead to lower stock prices.
Brian Bolan is a Stock Strategist
for Zacks.com. He is the Editor in charge of the Zacks Home Run Investor
service, a Buy and Hold service where he recommends the
stocks in the portfolio.
Brian is also the editor of Breakout Growth
a trading service that focuses on small cap stocks and
a risk limiting strategy. Subscribers get daily emails along
buy, and sell alerts.
Follow Brian Bolan on twitter at
Like Brian Bolan